A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2018.1527608
Abstract: Abstract Background: Much of the burden associated with schizophrenia is attributed to its early onset and chronic nature. Treatment with once monthly paliperidone palmitate (PP1M) is associated with lower healthcare utilization and better adherence as… read more here.
Keywords: young adult; utilization; treatment; medicaid ... See more keywords
Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2020641
Abstract: ABSTRACT Objectives Knowledge about the impact of body composition features on pharmacokinetics of newer long-acting injectable antipsychotics is limited. Methods We analyzed steady-state plasma concentrations of paliperidone in different body mass index (BMI), age, sex,… read more here.
Keywords: body; pp1m; paliperidone; plasma ... See more keywords
Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
Sign Up to like & getrecommendations! Published in 2021 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s313067
Abstract: Purpose Compared to once-monthly paliperidone palmitate (PP1M), once-every-3-months paliperidone palmitate (PP3M) reportedly increases treatment adherence. The objective of this study was to compare treatment patterns, utilization, and costs among Veterans Health Administration (VHA) patients with… read more here.
Keywords: paliperidone palmitate; pp1m; among veterans; vha patients ... See more keywords